President & Executive Director Of CK Life Sciences Int'l. (Holdings) Sold 37% Of Their Shares
President & Executive Director Of CK Life Sciences Int'l. (Holdings) Sold 37% Of Their Shares
Anyone interested in CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) should probably be aware that the President & Executive Director, Hing Lam Kam, recently divested HK$1.3m worth of shares in the company, at an average price of HK$0.55 each. The eyebrow raising move amounted to a reduction of 37% in their holding.
任何對CK生命科學國際(控股)有限公司(HKG:775)感興趣的人,可能應該知道,總裁兼執行董事Hing Lam Kam最近出售了價值130萬港元的公司股份,平均價格爲每股0.55港元。此舉使他們的持股減少了37%。
The Last 12 Months Of Insider Transactions At CK Life Sciences Int'l. (Holdings)
CK生命科學國際(控股)有限公司的過去12個月內部交易
In fact, the recent sale by Hing Lam Kam was the biggest sale of CK Life Sciences Int'l. (Holdings) shares made by an insider individual in the last twelve months, according to our records. So we know that an insider sold shares at around the present share price of HK$0.54. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
根據我們的記錄,Hing Lam Kam最近的出售是CK生命科學國際(控股)有限公司在過去十二個月內由內部人士進行的最大股份出售。因此,我們知道內部人士在目前的股價0.54港元左右出售了股份。儘管我們通常不喜歡看到內部人士的出售,但如果在較低價格出售則更令人擔憂。在這種情況下,較大規模的出售發生在當前價格附近,因此還算不錯(但仍然不是一個積極的信號)。
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
您可以在下面看到過去12個月內公司和個人的內部交易的視覺展示。通過點擊下面的圖表,您可以查看每筆內部交易的具體細節!
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找隱秘好股的人來說,這份包含近期內部購買的小盤公司免費清單,可能正是你所需要的。
Insider Ownership
內部持股情況
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. CK Life Sciences Int'l. (Holdings) insiders own 22% of the company, currently worth about HK$1.2b based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
對於普通股東來說,了解公司內部人士持有多少股票是值得關注的。我們通常希望看到相對較高的內部持股比例。CK生命科學國際(控股)公司的內部人士持有該公司22%的股份,按最近的股價計算,當前價值約爲12億港元。我喜歡看到這種內部持股水平,因爲這增加了管理層考慮股東最佳利益的可能性。
So What Do The CK Life Sciences Int'l. (Holdings) Insider Transactions Indicate?
那麼,CK生命科學國際(控股)公司的內部交易暗示了什麼?
An insider sold stock recently, but they haven't been buying. Despite some insider buying, the longer term picture doesn't make us feel much more positive. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Our analysis shows 3 warning signs for CK Life Sciences Int'l. (Holdings) (2 shouldn't be ignored!) and we strongly recommend you look at these before investing.
一位內部人士最近出售了股票,但他們並沒有買入。儘管有一些內部購買,但從長遠來看,這種情況讓我們感覺並不太樂觀。看到高比例的內部持股是件好事,但內部人士的出售讓我們保持謹慎。因此,這些內部交易可以幫助我們建立對股票的理論,但了解該公司面臨的風險也是值得的。我們的分析顯示CK生命科學國際(控股)公司有3個警告信號(其中2個不容忽視!),我們強烈建議你在投資前關注這些。
But note: CK Life Sciences Int'l. (Holdings) may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:CK生命科學國際(控股)公司可能不是最佳的買入股票。所以請查看這個免費的有趣公司名單,這些公司具有高ROE和低負債。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
在本文中,內部人士是指那些向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接權益的私人處置,但不包括衍生交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋嗎?對內容有疑慮嗎?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
本文由Simply Wall ST撰寫,屬於一般性質。我們提供基於歷史數據和分析師預測的評論,僅使用無偏見的方法,我們的文章並不意圖提供財務建議。它不構成對買入或賣出任何股票的推薦,也未考慮您的目標或財務狀況。我們旨在提供基於基本數據的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中沒有持倉。
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因